Company news
Hls Therapeutics, Inc. (TSX:HLS) news
Every Hls Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
HLS Therapeutics Announces Q2 2026 Financial Results
August 12, 2026
HLS Therapeutics Provides Update on NILEMDO™ Market Access
August 5, 2026
HLS Therapeutics to Host Q2 2026 Financial Results Conference Call
July 29, 2026
HLS Therapeutics Announces Q1 2026 Financial Results
May 15, 2026
HLS Therapeutics to Host Q1 2026 Financial Results Conference Call
May 1, 2026
HLS Therapeutics to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2026
HLS Therapeutics Announces Fiscal 2025 Financial Results
March 12, 2026
HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk...
March 5, 2026
HLS Therapeutics to Host Fiscal 2025 Financial Results Conference Call
February 26, 2026
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular...
November 18, 2025
HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovas...
November 18, 2025
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardio...
November 18, 2025
HLS Therapeutics Announces Q3 2025 Financial Results
November 13, 2025
HLS Therapeutics to Host Q3 2025 Financial Results Conference Call
October 30, 2025
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
October 14, 2025
HLS Therapeutics and Amarin Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
October 14, 2025
HLS Therapeutics Announces New Credit Agreement
August 20, 2025
HLS Therapeutics Announces Q2 2025 Financial Results
August 14, 2025
HLS Therapeutics to Host Q2 2025 Financial Results Conference Call
July 31, 2025
HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan
July 2, 2025
HLS Therapeutics Announces Reimbursement for Vascepa® under Nova Scotia's Provincial Drug Plan
July 2, 2025
HLS Therapeutics Reports Annual Meeting Results
June 20, 2025
HLS Therapeutics Announces Q1 2025 Financial Results
May 8, 2025
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
HLS Therapeutics partners with Esperion Therapeutics to commercialize NEXLETOL® and NEXLIZET® in Canada
May 8, 2025
HLS Therapeutics to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
April 28, 2025
HLS Therapeutics to Host Q1 2025 Financial Results Conference Call
April 24, 2025
HLS Therapeutics Announces Fiscal 2024 Financial Results and Normal Course Issuer Bid
March 13, 2025
HLS Therapeutics Appoints Christine Elliott to its Board of Directors
March 13, 2025
HLS Therapeutics to Host Fiscal 2024 Financial Results Conference Call
February 27, 2025
HLS Therapeutics Announces Q3 2024 Financial Results
November 7, 2024
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call
October 24, 2024
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference
August 28, 2024
HLS Therapeutics Announces Q2 2024 Financial Results
August 8, 2024
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
July 29, 2024
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call
July 25, 2024
HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust
July 2, 2024
HLS Therapeutics Announces Q1 2024 Financial Results
May 9, 2024
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
April 25, 2024
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 9, 2024
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
April 8, 2024
HLS Therapeutics Announces Fiscal 2023 Financial Results
March 14, 2024
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
February 29, 2024
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
February 6, 2024
HLS Therapeutics Announces CFO Departure
December 18, 2023
New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placeb...
November 14, 2023
HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid
November 9, 2023
HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call
October 26, 2023
HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference
September 6, 2023
HLS Therapeutics Announces Updates to its Credit Agreement
August 14, 2023